Cargando…
The coming of age of liquid biopsy in neuro-oncology
The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumours, targeted sequencing of cell-free DNA (cfDNA) from CSF may help differential diagnosis when surgery is not recommended and be more representative of tumour heterogeneity than surgical specimen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545511/ https://www.ncbi.nlm.nih.gov/pubmed/37289981 http://dx.doi.org/10.1093/brain/awad195 |
_version_ | 1785114687099109376 |
---|---|
author | Berzero, Giulia Pieri, Valentina Mortini, Pietro Filippi, Massimo Finocchiaro, Gaetano |
author_facet | Berzero, Giulia Pieri, Valentina Mortini, Pietro Filippi, Massimo Finocchiaro, Gaetano |
author_sort | Berzero, Giulia |
collection | PubMed |
description | The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumours, targeted sequencing of cell-free DNA (cfDNA) from CSF may help differential diagnosis when surgery is not recommended and be more representative of tumour heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient follow-up. Confounding factors may be represented by cfDNA variations due to concomitant pathologies (inflammatory diseases, seizures) or clonal haematopoiesis. Pilot studies suggest that methylome analysis of cfDNA from plasma and temporary opening of the blood–brain barrier by ultrasound have the potential to overcome some of these limitations. Together with this, an increased understanding of mechanisms modulating the shedding of cfDNA by the tumour may help to decrypt the meaning of cfDNA kinetics in blood or CSF. |
format | Online Article Text |
id | pubmed-10545511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105455112023-10-04 The coming of age of liquid biopsy in neuro-oncology Berzero, Giulia Pieri, Valentina Mortini, Pietro Filippi, Massimo Finocchiaro, Gaetano Brain Update The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumours, targeted sequencing of cell-free DNA (cfDNA) from CSF may help differential diagnosis when surgery is not recommended and be more representative of tumour heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient follow-up. Confounding factors may be represented by cfDNA variations due to concomitant pathologies (inflammatory diseases, seizures) or clonal haematopoiesis. Pilot studies suggest that methylome analysis of cfDNA from plasma and temporary opening of the blood–brain barrier by ultrasound have the potential to overcome some of these limitations. Together with this, an increased understanding of mechanisms modulating the shedding of cfDNA by the tumour may help to decrypt the meaning of cfDNA kinetics in blood or CSF. Oxford University Press 2023-06-08 /pmc/articles/PMC10545511/ /pubmed/37289981 http://dx.doi.org/10.1093/brain/awad195 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Update Berzero, Giulia Pieri, Valentina Mortini, Pietro Filippi, Massimo Finocchiaro, Gaetano The coming of age of liquid biopsy in neuro-oncology |
title | The coming of age of liquid biopsy in neuro-oncology |
title_full | The coming of age of liquid biopsy in neuro-oncology |
title_fullStr | The coming of age of liquid biopsy in neuro-oncology |
title_full_unstemmed | The coming of age of liquid biopsy in neuro-oncology |
title_short | The coming of age of liquid biopsy in neuro-oncology |
title_sort | coming of age of liquid biopsy in neuro-oncology |
topic | Update |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545511/ https://www.ncbi.nlm.nih.gov/pubmed/37289981 http://dx.doi.org/10.1093/brain/awad195 |
work_keys_str_mv | AT berzerogiulia thecomingofageofliquidbiopsyinneurooncology AT pierivalentina thecomingofageofliquidbiopsyinneurooncology AT mortinipietro thecomingofageofliquidbiopsyinneurooncology AT filippimassimo thecomingofageofliquidbiopsyinneurooncology AT finocchiarogaetano thecomingofageofliquidbiopsyinneurooncology AT berzerogiulia comingofageofliquidbiopsyinneurooncology AT pierivalentina comingofageofliquidbiopsyinneurooncology AT mortinipietro comingofageofliquidbiopsyinneurooncology AT filippimassimo comingofageofliquidbiopsyinneurooncology AT finocchiarogaetano comingofageofliquidbiopsyinneurooncology |